(Z)-5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyrimidine-2,4(1H,3H)-dione | 1338233-19-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (Z)-5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyrimidine-2,4(1H,3H)-dione
• 英文别名: 5-[(Z)-(2-imino-4-oxo-1,3-thiazolidin-5-ylidene)methyl]-1H-pyrimidine-2,4-dione
• CAS: 1338233-19-4
• 化学式: C₈H₆N₄O₃S
• 分子量: 238.227
• InChiKey: NNMCXOVNDAAFKV-RJRFIUFISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  139
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-甲酰基尿嘧啶 、 假硫代乙内酰脲 在 sodium acetate 作用下， 以 溶剂黄146 为溶剂， 反应 12.0h， 生成 (Z)-5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyrimidine-2,4(1H,3H)-dione
  参考文献：
  名称：

  Synthesis and evaluation of compounds that induce readthrough of premature termination codons

  摘要：

  A structure-activity relationship (SAR) study was carried out to identify novel, small molecular weight compounds which induce readthrough of premature termination codons. In particular, analogs of RTC13, 1, were evaluated. In addition, hypothesizing that these compounds exhibit their activity by binding to the ribosome, we prepared the hybrid analogs 13 containing pyrimidine bases and these also showed good readthrough activity. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.07.107

文献信息

• PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS
  申请人：GATTI Richard A.

  公开号：US20130274283A1

  公开（公告）日：2013-10-17

  Premature termination codons readthrough compounds, composition thereof, and methods of making and using the same are provided.

  提供了关于早期终止密码子读穿化合物、其组合物以及制备和使用方法的信息。
• [EN] READ-THROUGH COMPOUND PRODRUGS SUPPRESSING PREMATURE NONSENSE MUTATIONS<br/>[FR] PROMÉDICAMENTS CONSTITUÉS DE COMPOSÉS DE TRANSLECTURE SUPPRIMANT LES MUTATIONS NON-SENS PRÉMATURÉES
  申请人：UNIV CALIFORNIA

  公开号：WO2015109248A1

  公开（公告）日：2015-07-23

  Premature termination codon readthrough prodrug compounds, compositions thereof, and methods of making and using the same are provided. In certain embodiments, the compounds are of Formula Ia or a pharmaceutically acceptable salt, solvate, polymorph, hydrate, ester, isomer, stereoisomer, or tautomer thereof, wherein R, A and W are as described herein.

  提供了早期终止密码子读穿前药物化合物、其组成物和制备和使用这些化合物的方法。在某些实施例中，这些化合物为公式Ia或其药用可接受的盐、溶剂和多晶形式、水合物、酯、异构体、立体异构体或互变异构体，其中R、A和W如本文所述。
• READ-THROUGH COMPOUND PRODRUGS SUPPRESSING PREMATURE NONSENSE MUTATIONS
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20160333003A1

  公开（公告）日：2016-11-17

  Premature termination codon readthrough prodrug compounds, compositions thereof, and methods of making and using the same are provided. In certain embodiments, the compounds are of Formula Ia or a pharmaceutically acceptable salt, solvate, polymorph, hydrate, ester, isomer, stereoisomer, or tautomer thereof, wherein R, A and W are as described herein.

  提供了过早终止密码子读穿前药物化合物、其组合物以及制备和使用这些化合物的方法。在某些实施方式中，这些化合物属于公式Ia或其药用可接受的盐、溶剂化合物、多晶形、水合物、酯、异构体、立体异构体或互变异构体，其中R、A和W如本文所述。
• Read-through compound prodrugs suppressing premature nonsense mutations
  申请人：The Regents of the University of California

  公开号：US10287283B2

  公开（公告）日：2019-05-14

  Premature termination codon readthrough prodrug compounds, compositions thereof, and methods of making and using the same are provided. In certain embodiments, the compounds are of Formula Ia or a pharmaceutically acceptable salt, solvate, polymorph, hydrate, ester, isomer, stereoisomer, or tautomer thereof, wherein R, A and W are as described herein.

  本发明提供了过早终止密码子通读原药化合物、其组合物及其制造和使用方法。在某些实施方案中，所述化合物为式 Ia 或其药学上可接受的盐、溶液、多晶型、水合物、酯、异构体、立体异构体或同系物、 其中 R、A 和 W 如本文所述。
• US9255088B2
  申请人：——

  公开号：US9255088B2

  公开（公告）日：2016-02-09